The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
Open accessAbstract
The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties. Second generation thalidomide analogues are distinct compounds with enhanced therapeutic potential. Although these compounds are beginning to enter trials for the treatment of cancer there is very little information regarding the anti-angiogenic activity of these clinically relevant compounds. Furthermore, it is not known how the various immunomodulatory activities of these compounds relate to anti-angiogenic activity. In this study we assessed the anti-angiogenic activity of compounds from both IMiD and SelCID classes of analogues using a novel in vitro multicellular human assay system and the established rat aorta assay. Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide. The anti-angiogenic potency of the analogues was not related to inhibition of endothelial cell proliferation, nor their TNF-alpha/PDE type 4 inhibitory properties. However, anti-migratory effects in vitro and inhibition of tumour growth in vivo was observed with the analogue IMiD-1 (clinically known as REVIMID). Our results show that anti-angiogenic activity spans both currently defined classes of thalidomide analogue and is not related to their previously described immunomodulatory properties. Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Without blood vessels tumours cannot grow beyond a critical size or metastasise to another organ and therefore inhibition of such processes could be a strategy for tumour arrest (Carmeliet and Jain, 2000).”
BackgroundAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“The antiangiogenic activity of thalidomide is likely to be a contributing factor for its anti-tumour effects in MM (Singhal et al, 1999) for which it has been granted FDA approval.”
BackgroundThalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Bacterial endotoxin: molecular relationships of structure to activity and function
Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zähringer, U., Seydel, U., Di Padova, F., et al. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.2.8119492 · Cited by 1,607
Permanent cell line expressing human factor VIII-related antigen established by hybridization.
Edgell, C. J., McDonald, C. C., & Graham, J. B. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3734 · Cited by 1,488
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Self-citationGriffioen, A. W., & Molema, G. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01448-0 · Cited by 842
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Self-citationInhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Self-citation(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Nicosia, R. F., & Ottinetti, A. (1990) · PubMed · Cited by 597
Trends in cancer incidence and mortality in Scotland: description and possible explanations
Swerdlow, A., dos Santos Silva, I., Reid, A., Qiao, Z., Brewster, D., & Arrundale, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.424 · Cited by 532
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Fox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C., & Harris, A. L. (1995) · The Journal of Pathology · doi:10.1002/path.1711770310 · Cited by 436
Suramin: an anticancer drug with a unique mechanism of action.
Stein, C. A., LaRocca, R. V., Thomas, R., McAtee, N., & Myers, C. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.499 · Cited by 375
Comparison of three in vitro human ‘angiogenesis’ assays with capillaries formed in vivo
Donovan, D., Brown, N. J., Bishop, E. T., & Lewis, C. E. (2001) · Angiogenesis · doi:10.1023/a:1012218401036 · Cited by 342
An in vitro model of angiogenesis: Basic features
Bishop, E. T., Bell, G. T., Bloor, S., Broom, I. J., Hendry, N. F. K., & Wheatley, D. N. (1999) · Angiogenesis · doi:10.1023/a:1026546219962 · Cited by 307
Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent
Bauer, K. S., Dixon, S. C., & Figg, W. D. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00046-x · Cited by 295
Resveratrol and quercetin inhibit angiogenesis in vitro
Igura, K., Ohta, T., Kuroda, Y., & Kaji, K. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00443-8 · Cited by 229
Small, E. J., Meyer, M., Marshall, M. E., Reyno, L. M., Meyers, F. J., Natale, R. B., Lenehan, P. F., Chen, L., Slichenmyer, W. J., & Eisenberger, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1440 · Cited by 186
Marriott, J. B., Clarke, I., Dredge, K. S., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01954.x · Cited by 155
Self-citationOsugi, T., Oshima, Y., Fujio, Y., Funamoto, M., Yamashita, A., Negoro, S., Kunisada, K., Izumi, M., Nakaoka, Y., Hirota, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108246200 · Cited by 153
IL-12 regulates VEGF and MMPs in a murine breast cancer model
Dias, S., Boyd, R., & Balkwill, F. R. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981029)78:3<361::aid-ijc17>3.0.co;2-9 · Cited by 147
Takano, S., Gately, S. T., Neville, M. E., Herblin, W. F., Gross, J. L., Engelhard, H. H., Perricone, M. A., Eidsvoog, K., & Brem, S. S. (1994) · PubMed · Cited by 131
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.
Duda, D. G., Sunamura, M., Lozonschi, L., Kodama, T., Egawa, S., Matsumoto, G., Shimamura, H., Shibuya, K., Takeda, K., & Matsuno, S. (2000) · PubMed · Cited by 127
Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G. W., Shire, M. G., Stirling, D., & Dalgleish, A. G. (1998) · PubMed · Cited by 102
Self-citationThalidomide and a Thalidomide Analogue Inhibit Endothelial Cell Proliferation in vitro
Moreira, A. L., Friedlander, D. R., Shif, B., Kaplan, G., & Zagzag, D. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006202700039 · Cited by 91
Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G. W., Shire, M. G., Stirling, D., & Dalgleish, A. G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4236 · Cited by 89
Self-citationDanesi, R., Bianchi, S. D., Soldani, P., Campagni, A., Rocca, R. V. L., Myers, C., Paparelli, A., & Tacca, M. D. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.457 · Cited by 77
Effect of venous ulcer exudates on angiogenesis in vitro
Drinkwater, S. L., Smith, A., Sawyer, B. M., & Burnand, K. G. (2002) · British journal of surgery · doi:10.1046/j.1365-2168.2002.02085.x · Cited by 67
Thalidomide analogs and PDE4 inhibition
Muller, G. W., Shire, M. G., Wong, L. M., Corral, L. G., Patterson, R. T., Chen, Y., & Stirling, D. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00475-2 · Cited by 67
Self-citationTerai, Y., Abé, M., Miyamoto, K., Koike, M., Yamasaki, M., Ueda, M., Ueki, M., & Sato, Y. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1122 · Cited by 62
Immunotherapeutic and antitumour potential of thalidomide analogues
Marriott, J. B., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.4.675 · Cited by 52
Self-citation
Cited by
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Self-citationThe evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Self-citationMechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Anti-TNF-α therapies: the next generation
Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., & Moldawer, L. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1175 · Cited by 576
Metadata
- Authors
- Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G.
- Venue
- British Journal of Cancer
- Published
- 2002-10-29
- Volume
- 87
- Issue
- 10
- Pages
- 1166-1172
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2171194005
- Cited by
- 296
- References
- 36
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.